In melanoma tumor cells show intrinsic resistance to BRAF inhibition by sustaining a de-differentiated, mesenchymal-like, MITFlow/AXLhigh transcriptional profile15, or may switch towards this phenotype upon MAPK pathway inhibition16. This evidence concerns the gene BRAF and melanoma.